Group 1 - Recent control change, subsidiary cancellations, and expected losses have occurred at the company [1] - The stock price reached a historical high of 70 CNY per share on January 26, 2026, and closed at 62.19 CNY per share on February 11, 2026, reflecting market expectations regarding the control change [2] - A partial tender offer was initiated by Wang Qingtai and Cao Xiaobing on January 21, 2026, to acquire 19.44 million shares at a price of 32.07 CNY per share, representing 24.30% of the total share capital, with a funding requirement of 623 million CNY fully secured [3] Group 2 - The company is accelerating the cleanup of loss-making assets, with its wholly-owned subsidiary, Tibet Chenyun Industrial Co., Ltd., being deregistered on January 22, 2026, and Wuhan Jianuo Kang Pharmaceutical Technology Co., Ltd. also announcing deregistration on February 10, 2026, to enhance asset management efficiency [4] - The company expects a net profit loss attributable to shareholders of 76.24 million to 99.12 million CNY for the full year of 2025, primarily due to price and sales declines of its main product, sodium acetate Ringer's injection, after being included in the national procurement [5]
多瑞医药控制权变更与业绩预告引关注